close

Products

Date: 2017-10-19

Type of information: Granting of a patent

Product name: CRISPR technology

Compound: CRISPR technology

Therapeutic area: Technology - Services

Action mechanism: gene editing technology CRISPR genome-editing technology allows the precise modification of chromosomes in living cells. It is advancing treatment options for some of the toughest medical conditions faced today. CRISPR applications are far-ranging —from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.

Company: Merck KGaA (Germany)

Disease:

Latest news:

  • • On October 19, 2017, Merck KGaA announced that the Canadian Patent Office has issued a “Notice of Allowance” for the company’s patent application covering the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells. The forthcoming Canadian patent, entitled “CRISPR-BASED GENOME MODIFICATION AND REGULATION,” covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR. Scientists can replace a disease-associated mutation with a beneficial or functional sequence, a method important for creating disease models and gene therapy. Additionally, scientists can use the method to insert transgenes that label endogenous proteins for visual tracking within cells. Once formally granted, the Canadian patent will extend the protection of Merck KGaA's CRISPR integration technology into North America for the first time, further strengthening the company's patent portfolio. The Australian Patent Office granted Merck KGaA its first CRISPR patent in June of 2017, followed by the grant of a European patent in September of 2017. In May 2017, Merck KGaA announced its alternative CRISPR genome-editing method, called proxy-CRISPR. Unlike other systems, the proxy-CRISPR technique of Merck KGaA, Darmstadt, Grermany, can cut previously unreachable genomic locations, making CRISPR more efficient, flexible and specific, and giving researchers more experimental options. Merck KGaA has filed several patent applications on its proxy-CRISPR technology, and those applications are just the latest of multiple CRISPR patent filings made by the company since 2012.

Patents:

Submission of marketing authorization application USA :

Submission of marketing authorization application UE:

Withdrawal of marketing authorization application USA:

Withdrawal of marketing authorization application UE:

US authorization:

UE authorization:

Favourable opinion UE:

Favourable opinion USA:

Orphan status USA:

Orphan status UE:

Pediatric exclusivit _USA:

Pediatric exclusivity UE:

OTC status:

Other news:

Is general: Yes